Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
HYQVIA® [Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase], the Only Once-a-Month – Every Three or Four Weeks – Subcutaneous Immunoglobulin , is Now Approved for... | April 11, 2023
United States European Union Deficiency Foundation Drug Administration Takeda Pharmaceutical Company Limited Exchange Commission
Source: marketscreener.com